Class Action Lawsuit Filed Against Gossamer Bio, Inc. Over Failed Clinical Trial Results
A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) following the failure of its Phase 3 PROSERA study, which did not meet its primary endpoint. The company's stock price dropped significantly after the announcement, and investors are being urged to contact legal counsel. The lawsuit alleges potential securities fraud.
Tickers: $GOSS
Topics: class action lawsuit Gossamer Bio Phase 3 trial failure securities fraud stock price drop